Endothelin is a 21-residue peptide formed during incubation of isolated porcine endothelial cells. Due to its pronounced vasoconstrictor activity, endothelin has been proposed to play a role in the regulation of vascular tone. We studied the effects of synthetic endothelin (0.1-10 nM) on coronary flow, mechanical performance, myocardial oxygen uptake, and formation of purines, and outflow of 6-ketoprostaglandin F,a (metabolite of prostacyclin) in rabbit hearts perfused with saline by the Langendorff method. Endothelin dose-dependently decreased the coronary flow, at 10 nM, by about 75%. Heart rate, ventricular contractility, myocardial oxygen uptake, and purine release were affected by endothelin no more than by a corresponding mechanical reduction of the coronary flow. In contrast, the diastolic relaxation appeared to be directly diminished by endothelin. The concentration of 6-ketoprostaglandin F,. in the cardiac effluent was dose-dependently elevated by about 14 times by endothelin (10 nM) (p <0.001). A corresponding mechanical restriction of the coronary flow insignificantly affected the effluent concentration of 6-ketoprostaglandin F,a. The calcium channel blocker nifedipine (1 JAM) completely abolished the decrease in diastolic relaxation induced by endothelin and markedly counteracted the peptide-induced increase in effluent concentration of 6-ketoprostaglandin Fia, but did not affect the vasoconstrictor activity. These data demonstrate that endothelin induces vasoconstriction and facilitates the outflow of prostacyclin in the rabbit heart. In addition, the peptide appears to affect diastolic relaxation in this organ. (Circulation Research 1990;66: 46-54) In the last few years it has become increasingly apparent that the vascular endothelium may modulate the tone of the blood vessels by producing powerful vasodilators (endotheliumderived relaxing factor and prostacyclin) or vasoconstrictor(s) (endothelium-derived constricting factor).l 2 In comparison to the extensive studies performed to characterize the actions and nature of endotheliumderived relaxing factor, relatively little is known about endothelium-derived constricting factor. Endothelium-dependent contractions have been demonstrated in response to different stimuli such as hypoxia,2 pressure changes,3 electrical stimulation,4 acetylcholine,5 and arachidonic acid.6 Also, a basal release of endothelium-derived constricting factor has been reported from cultured endothelium, suggesting a physiological role for the compound.7 The chemical identification of endothelium-derived constricting factor is still under investigation, and both peptide7 and prostanoid56 structures of endotheliumderived constricting factor have been proposed. Recently a novel vasoconstrictor agent was isolated from the supernatant of cultured porcine endothelial cells. It was identified as a 21-residue peptide and named endothelin.8 Endothelin contracts isolated vessels from several organs and species, with a reported EC50 at least one order of magnitude lower than that of other known vasoconstrictors.8,9 Endothelin is a vasoconstrictor also in vivo, as shown in denervated rats.8 Besides, the peptide has been reported to stimulate the secretion of atrial natriuretic peptide from cultured rat atrial myocytes.10
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Recently a novel vasoconstrictor agent was isolated from the supernatant of cultured porcine endothelial cells. It was identified as a 21-residue peptide and named endothelin.8 Endothelin contracts isolated vessels from several organs and species, with a reported EC50 at least one order of magnitude lower than that of other known vasoconstrictors.8,9 Endothelin is a vasoconstrictor also in vivo, as shown in denervated rats. 8 Besides, the peptide has been reported to stimulate the secretion of atrial natriuretic peptide from cultured rat atrial myocytes.10 isolated rabbit heart were investigated. In addition, the possible effect of endothelin on the formation of prostacyclin in the heart was studied.
Materials and Methods Perfusion of Rabbit Hearts
A total of 52 New Zealand White rabbits of either sex, weighing 1.5-2.7 kg, were used for the study. After injection of heparin (1,000 IU/kg) into a marginal ear vein the animals were stunned by cervical dislocation and subsequently exsanguinated through the left carotid artery. A catheter was rapidly inserted into the aorta, allowing coronary perfusion to be quickly reestablished. The pulmonary artery was also cannulated. The heart was then dissected out and transferred to the perfusion apparatus, in which it was perfused according to Langendorff at a pressure of 5.6 kPa and a temperature of 380 C with a modified Tyrode's solution of the following millimolar composition: NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 1.0, NaHCO3 11.9, NaH2PO4 0.4, EDTA 0.01, and glucose 5.6. The solution was aerated with 3% CO2 in 02, giving a final pH of 7.3 and Po2 of 90 kPa.
The apex of the heart was attached to a lever connected to an isotonic transducer (Harvard Apparatus, Millis, Massachusetts). The signal was recorded on a polygraph (model 7D, Grass Instruments, Quincy, Massachusetts) and calibrated in millimeters. Quantitative estimation of the systolic apical movement of the heart, as well as of the end-diastolic position of the apex, was performed from the chart. The coronary flow rate was continuously followed by timed collection of the effluent in pretared beakers, which were weighed on an ordinary laboratory scale.
Protocol
After an initial stabilization period that lasted for about 30 minutes, the experiment was started by collection of basal effluent during 3 minutes. Then, a 5-minute infusion of endothelin (Peninsula Labs, Belmont, California) commenced, followed by a 30-minute perfusion without the drug. Endothelin was dissolved in saline and added directly to the perfusate, giving a final concentration of 0.1 nM (four hearts), 1 nM (eight hearts), 5 nM (five hearts), or 10 nM (eight hearts). Five hearts were given endothelin (10 nM) together with nifedipine (1-10 ,uM; Bayer AG). Another six hearts were given endothelin (5 nM) together with indomethacin (50 gM; Sigma Chemical, St. Louis, Missouri), and six more hearts were given endothelin (5 nM) together with aminophylline (0.1 mM; Teofyllamin ACO, Solna, Sweden). In a separate group of experiments, 10 hearts were subjected to a mechanical flow reduction by introduction of a roller pump into the perfusion system. In this series, the hearts were exposed in random order to each of four 5-minute periods of reduced coronary flow, amounting to 83%, 59%, 37%, or 25%, respectively, of their spontaneous coronary flow. The flow reduction periods were separated by 20-minute periods of perfusion at normal flow rate. The magnitude of the flow reductions were selected to give flow rates corresponding to those obtained in the series of hearts exposed to endothelin, in which endothelin (0.1 nM) reduced the flow to 83% of control and endothelin (1, 5, and 10 nM) reduced the flow to 59%, 37%, and 25%, respectively, of control coronary flow.
Samples for analysis of purines and of 6-ketoprostaglandin F1,, (6-keto-PGF,,,') in the cardiac effluent were drawn during the basal perfusion period and after 3-5 minutes of exposure to endothelin or mechanical flow reduction. Samples for analysis of Po2 in the cardiac effluent were taken from the pulmonary artery catheter during the basal perfusion period and at the end of the endothelin exposure or mechanical flow reduction.
Analyses
All effluent samples were collected on ice. After volume determination, separate portions of the effluent for analysis of purines and of 6-keto-PGF10 were frozen and kept at -20°C until analysis.
Purines were analyzed in unextracted samples as adenosine, inosine, and hypoxanthine by use of liquid chromatography with adsorbance detection.11 Since the proportion of adenosine, inosine, and hypoxanthine varied between the samples, the sum of these three nucleotide metabolites is presented.
The prostacyclin metabolite 6-keto-PGF1, was analyzed with a stable isotope dilution technique using gas chromatography/mass spectrometry as follows. After addition of a tetradeuterated internal standard of 6-keto-PGFl, (1 ng/ml) a 2.5-ml portion of the sample was treated for 40 minutes with 30 mg methoxyamine hydrochloride dissolved in 0.75 ml acetate buffer (1.5 M, pH 4.8). After acidification, the reaction products were adsorbed on a disposable C18 cartridge, washed, and eluted with 2 ml ethyl acetate. After evaporation the residue was dissolved in 1 ml of 15% isopropanolol in ethyl acetate (vol/vol) and applied to a disposable silica cartridge. After washing, the column was eluted with 2 ml of 40% isopropanolol in ethyl acetate (vol/vol). After evaporation to dryness, the sample was converted to its pentafluorobenzyl ester, dried, and dissolved in 2 ml of 45% ethyl acetate in hexane (vol/vol). It was subsequently adsorbed to a dihydroxy column (2-OH; Analytichem), washed, and eluted with 2 ml of 60% ethyl acetate in hexane (vol/vol). After evaporation, the residue was converted to its trimethylsilyl ether.
On analysis, the sample was dried and dissolved in ratio (m/z) of 614 for the sample content of 6- keto-PGFia and at m/z=618 for the tetradeuterated internal standard.
Calculations
Heart rate was calculated from the recording chart. The systolic apical movement and the endothelin-induced change in diastolic apical position were also calculated from this chart and expressed in millimeters.
All data are presented as mean±SEM. Figures within brackets indicate number of experiments. Standard procedures have been used for calculation of statistical differences. A value of pcO.05 has been considered as significant.
Results
The mean wet weight of the hearts was 5.8±0.1 g. After the stabilization period the basal coronary flow was 38±2 ml/min (n=24). The spontaneous beating rate was 163±6 beats/min (n = 24). The systolic apical movement (2-3 mm) and the diastolic apical position were stable during the basal period. The fractional oxygen extraction was 0.51±0.04, and the myocardial oxygen consumption was 3.2±0.2 gumol/min/g heart weight. The pH of the effluent was 7.20±0.03.
Infusion of endothelin (0.1-10 nM) induced a dose-dependent decrease in coronary flow (Figure la) . At the end of the 5-minute exposure to endothelin the coronary flow was reduced to 83±6% (0.1 nM, p<O.05), to 59±6% (1 nM,p<0.001), to 37±3% (5 nM,p<0.001), and to 25±6% (10 nM,p<0.001), respectively, of the basal coronary flow. The onset of the coronary vasoconstrictor action was rapid; after 1 minute of exposure to endothelin (10 nM), the flow was reduced to 44±7% (p<0.001, Figure lb) . After the end of the exposure the vasoconstrictor activity was slowly and incompletely reversed; after 30 minutes of washout, the coronary flow was still reduced to about 45% in comparison to basal flow ( Figure  lb ). Bolus injection of 0.1 mmol nitroprusside (Nipride, Roche Laboratories, Nutley, New Jersey) early during the washout period to hearts previously exposed to endothelin (5 nM) increased the coronary flow from 36±6% to 73±17% (n=4) of the basal (preendothelin) flow (see also Figure 2 ).
In parallel to the vasoconstriction, endothelin at 10 nM dose-dependently lowered the spontaneous heart rate by 29 ±7%. The decrease in heart rate during endothelin exposure did not differ from that elicited by a quantitatively similar mechanical flow reduction only ( Figure 3) .
The systolic apical movement was insignificantly affected by endothelin and did not differ from that induced by a quantitatively similar mechanical reduction in coronary flow (Figures 2 and 4) .
The end-diastolic apical position was dosedependently changed toward less efficient relaxation by endothelin. A 2 and 4). The difference between endothelin and mechanical flow reduction in impairing the diastolic relaxation is highly significant (p<0.001, two-way analysis of variance). Endothelin (10 nM) increased the oxygen extraction of the heart to 80+3% (p<0.02), decreased the oxygen uptake to 1.1±0.3 ,umol/min/g wet wt (p<0.01), and decreased the pH of the effluent to 6.9±0.06 (p<0.025). Hence, despite a more efficient myocardial extraction of oxygen, the uptake of oxygen in the heart decreased during the endothelininduced coronary vasoconstriction (Figure 3) . The basal outflow of purines was 38.5±6.2 nmol/3 min, and the basal concentration of purines in the effluent was 0.34±0.06 ,uM. Infusion of endothelin (0.1 or 1 nM) did not affect the outflow or the effluent concentration of purines. Endothelin (5 and 10 nM) increased the outflow of purines about four times (p<0.05, Figure 3) . The concentration of purines in the effluent was also elevated by endothelin, about seven times (5 nM, p<0.01) and 13.5 times (10 nM, p<0.01), respectively. The effects of endothelin on myocardial oxygen consumption, effluent oxygen content and pH, and outflow of purines did not differ from the corresponding actions elicited by a quantitatively similar mechanical reduction in coronary flow ( Figure 3 ). In the presence of nifedipine (1 pgM), endothelin (10 ,M) was unable to elicit any change in diastolic apical position, as shown in Figure 5 . In contrast, the effects of the peptide on coronary flow, heart rate, myocardial oxygen uptake, and outflow of purines were unaffected by this dose of nifedipine ( Figure 6 ). Nifedipine (10 ,uM) partly counteracted the effects of endothelin on coronary flow and on purine outflow ( Figure 6 ). At this concentration, nifedipine almost completely abolished the mechanical activity of the heart, implying that the atria displayed weak contractility at a lowered beating rate and the ventricles were asystolic. Due to the lack of ventricular activity, systolic apical movement and diastolic apical position were not measured when endothelin was given with the higher dose of nifedipine.
When endothelin (5 nM) was given together with aminophylline (0.1 mM) or indomethacin (50 ,M), coronary flow, mechanical performance, or outflow of purines did not differ from the corresponding values observed after administration of endothelin only ( Table 1 ).
The basal outflow of 6-keto-PGFi, was 30.4±4.4 ng/3 min, and the basal concentration of 6-keto-PGFla in the cardiac effluent was 0.26±0.04 ng/ml. Exposure to endothelin (1-10 nM) elicited an increase in the outflow of 6-keto-PGFia from the heart (p<0.001, two-way analysis of variance), while a corresponding mechanical reduction of the flow had no such effect. Furthermore, the concentration of 6-keto-PGFl, in the effluent was elevated more by endothelin than by a corresponding reduction in flow (p=0.001, two-way analysis of variance, Figure 7 ).
Nifedipine (1-10 gM) efficiently counteracted the increase in effluent concentration 6-keto-PGFia induced by endothelin (10 nM, Figure 8 ), and as a consequence, also the increased outflow of 6-keto-PGFl,, from the heart.
Discussion
In the present experiments, synthetic endothelin elicited a pronounced coronary vasoconstrictor effect in perfused rabbit hearts. Endothelin also affected the diastolic relaxation and stimulated the outflow of prostacyclin metabolite from the organ. These data demonstrate that the biological actions of endothelin are not restricted to contraction of vascular smooth muscle only.
The The mechanical performance of the heart was also affected by endothelin. The moderate, dosedependent bradycardia we observed appeared related to the vasoconstrictor action of the peptide, since mechanical reduction of the coronary flow had a similar negative chronotropic effect. In this connection, it may be noted that endothelin had a positive chronotropic action in isolated, spontaneously beating guinea pig atria.'8 Whether a similar direct effect of the peptide on pacemaker activity was absent in the present experiments or was masked by the vasoconstrictor action remains to be studied.
Endothelin also changed the apical position of the heart during diastole toward less efficient diastolic relaxation. This action of endothelin did not appear to be based on the flow reduction only, since mechan- to have positive inotropic action in guinea pig and rat atria19'20; such an action was not observed in the present experiments. Hence, also the effects of endothelin on myocardial contractility and relaxation may be tissue and species dependent. In this connection it is notable that the decrease in diastolic relaxation induced by endothelin was counteracted by nifedipine (1 ,uM). Parallel to the progressive coronary vasoconstriction, endothelin induced a dose-dependent decrease in myocardial oxygen consumption, despite an increase in myocardial oxygen extraction, and a lowered pH in the effluent. These actions of endothelin were clearly Langendorff-perfused rabbit hearts. Infusion time indicated by the box. Upper diagram displays coronaryflow and heart rate, and the lower tracing represents the apical movement of the heart. Note that the baseline of the apical tracing is stable during the infusion, in contrast to the corresponding baseline demonstrated in Figure 2 . Nifedipine impaired the systolic apical movement slightly, indicating a negative inotropic effect by the drug. related to the vasoconstriction since mechanical flow reduction elicited similar effects. The outflow of purines was also increased by endothelin (5-10 nM). An increased cardiac outflow of adenosine and its degradation products, inosine and hypoxanthine, usually reflects impairment of oxygen supply.21'22 Also, this effect of endothelin appeared to be flow dependent, inasmuch as mechanical flow reduction caused an increase in purine outflow that did not differ from that caused by endothelin. Hence, it appears that at least a major part of the change in myocardial metabolism in response to endothelin exposure in the present study was caused by the coronary vasoconstriction and subsequent oxygen deprivation.
Ventricular performance was monitored by recording of apical movement during the cardiac cycle. The upward apical movement, representing the systolic shortening of the heart, was not affected either by endothelin (0.1-1 nM) or by a corresponding mechanical reduction in flow. This may seem surprising in c E CD D% 59% 37% coronary flow in relation to basal light of the decreased myocardial oxygen uptake and increased purine outflow. However, the Langendorffperfused rabbit heart has considerable glycolytic capacity, as revealed by a marked increase in lactate release during oxygen deprivation.23 Obviously, the glycolytic capacity of the present hearts was sufficient to meet the reduction in oxygen uptake and thereby to allow mechanical performance to be maintained.
Nifedipine (1 ,uM) did not significantly counteract the endothelin-induced release of purines from the heart. This agrees with the lack of effect of this concentration of nifedipine on endothelin-induced vasoconstriction. In contrast, nifedipine (10 1uM) completely reversed endothelin-induced outflow of purines, despite no more than a partial reversal of the vasoconstriction. We interpret this lowered outflow of purines in the presence of nifedipine (10 ,uM) as secondary to a diminished myocardial demand of oxygen; as stated above, nifedipine (10 ,uM) The efflux of the prostacyclin metabolite 6-ketoPGFia in this rabbit heart preparation is mainly of coronary origin.24 The efflux of 6-keto-PGF1, was also affected by endothelin. The concentration of 6-keto-PGF1, was elevated almost 10-fold by endothelin (5 nM), and by the highest concentration of endothelin applied (10 nM) the effluent concentration of 6-keto-PGFia was increased about 14 times. These data suggest that endothelin augmented the cardiac formation and release of prostacyclin. In contrast to its action on the efflux of purines, the effect of endothelin on cardiac prostacyclin synthesis can hardly be explained by the vasoconstriction induced by the peptide. Thus, mechanical reduction of coronary flow did not significantly affect the outflow of 6-keto-PGFi, and induced no more than a minor stimulatory effect on the effluent concentration of prostacyclin metabolite. Rather, the increased effluent concentration of 6-keto-PGFia during exposure to endothelin seems to be the result of a true stimulation of cardiac prostacyclin formation. Interestingly, nifedipine (1 ,uM) markedly counteracted the stimulatory effect of endothelin on prostacyclin formation, at a concentration that did not affect the coronary flow. The observation may indicate that endothelin acts via more than one mechanism in the heart.
The possible physiological impact of the marked increase in outflow of purines and 6-keto-PGFia from the heart during endothelin exposure was also studied. Adenosine and prostacyclin are potent coronary vasodilators and therefore might have counteracted the vasoconstrictor action of the peptide. However, neither the cyclooxygenase inhibitor indomethacin, at a concentration that markedly attenuated the formation of prostacyclin metabolite in the heart, nor the purinoceptor antagonist aminophylline, at a concentration sufficient to inhibit cardiac purinoceptors,S26 facilitated the vasoconstrictor action of endothelin. The lack of effect indicates that the amounts of adenosine and prostacyclin released under the prevailing conditions were unable to elicit any vasodilator activity in the coronary vessels.
In summary, the current study demonstrates that endothelin elicits significant effects on several aspects of cardiac function. The cardiac actions of endothelin, involving interference with vascular tone and formation of prostacyclin and possibly diastolic relaxation, renders endothelin a compound of considerable importance also in relation to cardiac physiology under normal and pathological conditions.
